Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 549


Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.

J Infect Dis. 2007 Oct 1;196(7):1026-32. Epub 2007 Aug 20.


Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.

He Y, Meseda CA, Vassell RA, Merchlinsky M, Weir JP, Weiss CD.

Vaccine. 2010 Jan 8;28(3):699-706. doi: 10.1016/j.vaccine.2009.10.078. Epub 2009 Nov 1.


Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.


Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.

Jones-Trower A, Garcia A, Meseda CA, He Y, Weiss C, Kumar A, Weir JP, Merchlinsky M.

Virology. 2005 Dec 5;343(1):128-40. Epub 2005 Sep 13.


Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.

Kaever T, Meng X, Matho MH, Schlossman A, Li S, Sela-Culang I, Ofran Y, Buller M, Crump RW, Parker S, Frazier A, Crotty S, Zajonc DM, Peters B, Xiang Y.

J Virol. 2014 Oct;88(19):11339-55. doi: 10.1128/JVI.01491-14. Epub 2014 Jul 16.


Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.

Golden JW, Zaitseva M, Kapnick S, Fisher RW, Mikolajczyk MG, Ballantyne J, Golding H, Hooper JW.

Virol J. 2011 Sep 20;8:441. doi: 10.1186/1743-422X-8-441.


Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.

Kaever T, Matho MH, Meng X, Crickard L, Schlossman A, Xiang Y, Crotty S, Peters B, Zajonc DM.

J Virol. 2016 Apr 14;90(9):4334-45. doi: 10.1128/JVI.02878-15. Print 2016 May.


An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model.

Law M, Pütz MM, Smith GL.

J Gen Virol. 2005 Apr;86(Pt 4):991-1000.


Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.

Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, Hirst S, Villarreal L, Felgner PL, Crotty S.

J Virol. 2005 Sep;79(18):11724-33.


Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.

Golden JW, Josleyn MD, Hooper JW.

Vaccine. 2008 Jun 25;26(27-28):3507-15. doi: 10.1016/j.vaccine.2008.04.017. Epub 2008 Apr 28.


Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.

Galmiche MC, Goenaga J, Wittek R, Rindisbacher L.

Virology. 1999 Feb 1;254(1):71-80.


Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Wyatt LS, Earl PL, Eller LA, Moss B.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. Epub 2004 Mar 11.


Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Shinoda K, Wyatt LS, Irvine KR, Moss B.

Virol J. 2009 Mar 3;6:28. doi: 10.1186/1743-422X-6-28.


Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Meseda CA, Mayer AE, Kumar A, Garcia AD, Campbell J, Listrani P, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. doi: 10.1128/CVI.00040-09. Epub 2009 Jul 15.


Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.


Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.

Midgley CM, Putz MM, Weber JN, Smith GL.

J Gen Virol. 2008 Dec;89(Pt 12):2992-7. doi: 10.1099/vir.0.2008/004440-0.


Monitoring of human immunological responses to vaccinia virus.

Harrop R, Ryan MG, Golding H, Redchenko I, Carroll MW.

Methods Mol Biol. 2004;269:243-66. Review.


Supplemental Content

Support Center